Indefinite Delivery Contract 75D30123D16649
Award Date
6/14/23
Last Date to Order
6/6/24
Federal Agency
CDC Pittsburgh
Awardee
Novavax Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Novavax Inc. to provide adult COVID-19 vaccines. The contract has a ceiling value of $13,961,250 and a period of performance through May 31, 2025. As a prime contractor, Novavax will deliver COVID-19 vaccine products and services out of its Maryland facility to support the CDC's public health response. Novavax is an experienced federal contractor, having previously received a $45.7...
The federal contract IDV award is a $174 million Indefinite Delivery Contract (IDC) from the Centers for Disease Control and Prevention (CDC) to Novavax Inc. for the provision of adult COVID-19 vaccines. This multiple award contract has a period of performance through June 2024. Novavax, a biotechnology company that develops and produces recombinant protein nanoparticle vaccines, has previously provided COVID-19 vaccine research, development, and manufacturing services to the U.S. government...
The federal contract IDV award is for the provision of COVID-19 pediatric vaccines by Novavax Inc. (Novavax) to the Centers for Disease Control and Prevention (CDC). The $116 million IDV contract has an ultimate completion date of May 31, 2025 and is a multiple award IDV, meaning task orders will be competed among multiple awardees. Novavax has previously received federal contracts from the Department of the Army and has also served as a subcontractor on other government contracts. The purpose...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Moderna US, Inc. to provide pediatric COVID-19 vaccines. The contract has a ceiling value of $153,890,500 and a period of performance ending on May 31, 2026. Moderna US, Inc., a subsidiary of Modernatx, Inc., is a biotechnology company that specializes in developing and manufacturing mRNA therapeutics and vaccines. The company has received multiple federal contract awards to supply...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, for the procurement of pediatric COVID-19 vaccines. The contract has a total ceiling value of $1,009,243,769 and a period of performance from June 1, 2025, through May 31, 2026. The primary objective of this IDC is to provide the CDC with a reliable source for pediatric COVID-19 vaccines to support the Vaccines for Children (VFC)...
This federal contract IDV award from the Centers for Disease Control and Prevention (CDC) is for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children ages 0 through 18 years. The contract is a multiple award, indefinite delivery indefinite quantity (IDIQ) vehicle, with a ceiling value of $601,370,000 and a period of performance ending June 6, 2024. The prime contractor is Moderna US, Inc., a biotechnology company that develops and manufactures mRNA...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $1,517,947,500.00 and a period of performance from April 1, 2022 through March 31, 2023. It is a multiple award contract vehicle that will provide up to 23 standard pediatric vaccines to support CDC's Immunization Awardees and the Vaccines for...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a global pharmaceutical manufacturer, to provide COVID-19 pediatric vaccines. The contract has a ceiling value of $1,096,801,491.00 and a period of performance running through September 30, 2025. As the prime contractor, Pfizer will deliver a range of critical pharmaceutical products to support various federal healthcare programs, including the Vaccines for Children (VFC)...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Pfizer Inc. for the procurement of standard commercial COVID-19 vaccines with a pediatric indication for children aged 0 through 18 years. The contract has a $1,075,250,000.00 ceiling value and a performance period ending on June 6, 2024. The vaccines procured under this multiple-award IDC will support pediatric immunization programs through the Vaccines...